Evidence map›Paper›PMID 35967119›Full record

ArticleKidney international reports2022

Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrology-Peritoneal Dialysis Consensus Workshop Report.

Jenny I Shen, Yeoungjee Cho, Karine E Manera, Fiona Brown, Jie Dong, Muthana Al Sahlawi, Rafael G Acevedo, Htay Htay, Yasuhiko Ito, Talerngsak Kanjanabuch and 15 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 11 countries.

Jenny I ShenDivision of Nephrology and Hypertension, The Lundquist Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Yeoungjee ChoFaculty of Medicine, Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Karine E ManeraSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Fiona BrownDepartment of Nephrology, Monash University at Monash Medical Centre, Melbourne, Australia.
Jie DongRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Beijing, People's Republic of China.
Muthana Al SahlawiDepartment of Internal Medicine, College of Medicine, King Faisal University, Al-Hasa, Saudi Arabia.
Rafael G AcevedoRenal Unit, RTS San Fernando, Cali, Colombia.
Htay HtayDepartment of Renal Medicine, Singapore General Hospital, Singapore.
Yasuhiko ItoDivision of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Talerngsak KanjanabuchDivision of Nephrology, Department of Medicine and Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Sharon J NessimDivision of Nephrology, Jewish General Hospital, McGill University, Montreal, Canada.
Grace NgaruiyaSchool of Nursing, University of Nairobi, Nairobi, Kenya.
Beth PirainoUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Cheuk-Chun SzetoDepartment of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Isaac TeitelbaumDivision of Nephrology, Department of Medicine, University of Colorado, Aurora, Colorado, USA.
Noa AmirSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Jonathan C CraigCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Amanda BaumgartSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Andrea M GonzalezSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Nicole Scholes-RobertsonSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Andrea K ViecelliFaculty of Medicine, Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Martin WilkieDepartment of Nephrology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Allison TongSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Jeffrey PerlDivision of Nephrology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
SONG-PD Infection Workshop Investigators
The University of Sydney · AUTranslational Research Institute · AUAichi Medical University · JPChinese University of Hong Kong · HKChulalongkorn University · THFlinders University · AUJewish General Hospital · CAKing Faisal University · SAMonash Medical Centre · AUPeking University · CNSheffield Teaching Hospitals NHS Foundation Trust · GBSingapore General Hospital · SGSt. Michael's Hospital · CAUCLA Medical Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Nairobi · KEUniversity of Pittsburgh · US

Funding

Trajectories of Adherence to Cardiovascular Medications in Patients on DialysisK23DK103972 · NIDDK · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SHEN, JENNY I · 2015 to 2019
$934k
NIDDK NIH HHS K23 DK103972
6 · The paper itself

Abstract

Introduction: Peritoneal dialysis (PD)-related peritonitis is one of the leading causes of discontinuation of PD and is considered a critically important outcome for patients on PD. However, there is no universally accepted method of measuring this outcome in clinical trials. Methods: We convened an online consensus workshop to establish a core outcome measure for PD-related peritonitis in clinical trials. Results: A total of 53 participants, including 18 patients and caregivers, from 12 countries engaged in breakout discussions in this workshop. Transcripts were analyzed thematically. We identified the following 3 themes: (i) feasibility and applicability across diverse settings, which reflected the difficulty with implementing laboratory-based measures in resource-limited environments; (ii) ensuring validity, which included minimizing false positives and considering the specificity of symptoms; and (iii) being meaningful and tangible to patients, which meant that the measure should be easy to interpret, reflect the impact that symptoms have on patients, and promote transparency by standardizing the reporting of peritonitis among dialysis units. Conclusion: A core outcome measure for PD-related peritonitis should include both symptom-based and laboratory-based criteria. Thus, the International Society for Peritoneal Dialysis (ISPD) definition of peritonitis is acceptable. However, there should be consideration of reporting suspected peritonitis in cases where laboratory confirmation is not possible. The measure should include all infections from the time of catheter insertion and capture both the rate of infection and the number of patients who remain peritonitis free. A core outcome measure with these features would increase the impact of clinical trials on the care and decision-making of patients receiving PD.

Indexed as

core outcome measureperitoneal dialysisperitonitistrial design

Identifiers

PMID35967119
PMCPMC9366360
OpenAlexW4281565344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.